Abstract A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed. The glycoprotein is specifically bound by wheat germ agglutinin and also by the hydrophobically binding ligand Blue A (Cibacron Blue F3G-A) but does not bind to lysine. The glycoprotein is a necessary cofactor with Interleukin-1 in the biosynthesis of T-cell growth factor (I1-2). A process for producing a serum-free and mitogen-free I1-2 in vitro by adding the glycoprotein to a serum-free- and mitogen-free Interleukin-1 preparation is described. The method for producing the serum-free and mitogen-free Interleukin-1 is also described. A chemically defined T-cell growth culture medium containing the new glycoprotein as the only protein substance is used in the above process and also provides a means for studying regulation of T-cell lymphocyte growth. Inhibitors for the formation of T-cell blasts in cell mediated immunological response provide a powerful new tool for preventing host-graft rejection. These inhibitors are alkylating agents for serine esterase enzymes which have been found to be involved in the cell mediated immunological response system which generates natural Killer (NK) cells, the latter being responsible for graft rejection in a host.
A process for producing an Interleukin-1 preparation comprising (a) incubating isolated peripheral mononuclear blood cells in a serum-free liquid tissue culture medium for from about 18 to about 24 hours to remove serum proteins adhering to the cell membranes; (b) contacting the incubated blood cells with a mitogen for a period of about 4 to 12 hours to activate the monocytic cell population of the mononuclear blood cells for the production of Interleukin-1; (c) washing the activated cells with a sterile liquid to remove the mitogen; and (d) incubating the activated cells in a serum-free liquid tissue culture medium to collect Interleukin-1 in the liquid phase of the tissue culture medium to thereby obtain a preparation of Interleukin-1.
Claim 2
Dependent Claim
118 words
A process for producing an Interleukin-1 preparation comprising (a) incubating isolated peripheral mononuclear blood cells in a serum-free liquid tissue culture medium for from about 18 to about 24 hours to remove serum proteins adhering to the cell membranes; (b) contacting the incubated blood cells with a mitogen for a period of about 4 to 12 hours to activate the monocytic cell population of the mononuclear blood cells for the production of Interleukin-1; (c) washing the activated cells with a sterile liquid to remove the mitogen; and (d) incubating the activated cells in a serum-free liquid tissue culture medium to collect Interleukin-1 in the liquid phase of the tissue culture medium to thereby obtain a preparation of Interleukin-1.
Claim 3
Dependent Claim
26 words
The process of claim 1 wherein the isolated peripheral mononuclear blood cells used in step (a) are isolated promacrophage cells separated from peripheral mononuclear blood cells.
Claim 4
Dependent Claim
30 words
The process of claim 1 wherein the mitogen used in step (b) is phytohemagglutinin A and the incubated cells are left in contact with the mitogen for about 4 fours.
Claim 5
Dependent Claim
21 words
The process of claim 1 wherein in step (d) the activated cells are incubated for about 18 to about 24 hours.